Page last updated: 2024-09-05

tolvaptan and Cirrhosis, Liver

tolvaptan has been researched along with Cirrhosis, Liver in 72 studies

Research

Studies (72)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (9.72)	29.6817
2010's	47 (65.28)	24.3611
2020's	18 (25.00)	2.80

Authors

Authors	Studies
Eguchi, A; Iwasa, M; Shigefuku, R; Suzuki, T; Takei, Y; Tamai, Y; Tempaku, M	1
Abe, M; Hiasa, Y; Hirooka, M; Koizumi, Y; Nakamura, Y; Sunago, K; Tokumoto, Y; Watanabe, T; Yano, R; Yoshida, O; Yukimoto, A	1
Arase, Y; Hara, T; Hirose, S; Kagawa, T; Koizumi, J; Mishima, Y; Ono, S; Sekiguchi, T; Sekiguchi, Y; Shiraishi, K; Tsuruya, K	1
Hosoda, S; Kitagataya, T; Kohya, R; Kubo, A; Morikawa, K; Nakai, M; Ogawa, K; Ohara, M; Sakamoto, N; Sasaki, T; Sho, T; Suda, G; Tokuchi, Y; Yamada, R; Yoshida, S	1
Hu, YY; Wang, YD; Zhang, X; Zhao, CY	1
Aikata, H; Chayama, K; Fujino, H; Hiramatsu, A; Imamura, M; Kawaoka, T; Kodama, K; Morio, K; Murakami, E; Nakahara, T; Namba, M; Ohya, K; Tsuge, M; Uchikawa, S; Yamauchi, M	1
Abe, H; Arai, T; Atsukawa, M; Chuma, M; Fukunishi, S; Hattori, N; Hiraoka, A; Iio, E; Ikegami, T; Itokawa, N; Iwakiri, K; Iwasa, M; Kato, K; Kondo, C; Kumada, T; Michitaka, K; Nakagawa-Iwashita, A; Nozaki, A; Okubo, H; Okubo, T; Senoh, T; Tada, T; Takaguchi, K; Takei, Y; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsutsui, A; Uojima, H; Watanabe, T; Yokohama, K; Yoshida, Y	1
Chu, PS; Ebinuma, H; Ikura, A; Kanai, T; Morikawa, R; Nakamoto, N; Ojiro, K; Saito, H; Shiba, S; Taniki, N; Yamaguchi, A; Yamataka, K; Yoshida, A	1
Fukuta, Y; Hirano, T; Kurosaki, M; Okada, M; Sakaida, I; Terai, S	1
Kawagishi, N; Kitagataya, T; Kubo, A; Morikawa, K; Nakai, M; Nakamura, A; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Sho, T; Suda, G; Suzuki, K; Tokuchi, Y; Umemura, M; Yamada, R	1
Hiramine, Y; Hiwaki, T; Ido, A; Imamura, Y; Kanmura, S; Maenohara, S; Mawatari, S; Oku, M; Saishoji, A; Tokushige, K; Uto, H	1
Attia, H; El-Shabrawy, M; Emad Aboulhoda, B; Emam, M; Mishriki, A; Wanas, H	1
Alukal, JJ; John, S; Thuluvath, PJ	1
Chen, C; Chen, Y; Cheng, J; Ding, H; Gao, Y; Han, T; Ji, F; Jia, J; Jiang, X; Lv, N; Mao, Q; Mao, Y; Niu, J; Shang, J; Tang, J; Wang, Y; Wang, Z; Wei, Z; Zeng, M; Zhang, Q	1
Adachi, T; Okada, H; Onishi, H; Oyama, A; Shiraha, H; Takaki, A; Takeuchi, Y; Wada, N	1
Eguchi, Y; Hirashima, N; Ikejima, K; Ishikawa, T; Kawai, Y; Kawaratani, H; Kogiso, T; Komori, A; Matsumoto, N; Motoyama, H; Nakajima, T; Nojima, M; Onishi, M; Saito, S; Sawai, H; Shimada, N; Tanaka, Y; Tateyama, M; Terai, S; Uojima, H; Yoshiji, H	1
Enomoto, N; Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Komiyama, Y; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yamashita, K; Yasui, Y	1
Enomoto, N; Gotou, T; Hayashi, T; Higuchi, M; Itakura, J; Izumi, N; Komiyama, Y; Kubota, Y; Kurosaki, M; Nakanishi, H; Oh, W; Okada, M; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Yasui, Y	1
Hiramatsu, A; Hiramine, Y; Iwamoto, T; Izumi, N; Kawaratani, H; Kimura, M; Koike, K; Nakanishi, H; Okita, K; Sakaida, I; Terai, S; Uojima, H; Uto, H; Yoshiji, H	1
Hashimoto, E; Ikarashi, Y; Kobayashi, M; Kodama, K; Kogiso, T; Taniai, M; Tokushige, K; Torii, N; Yamamoto, K	1
Parekh, A; Patel, G; Rajaram, P; Subramanian, RM	1
Egashira, H; Hidaka, H; Ichita, C; Kako, M; Koizumi, K; Masuda, S; Nakayama, T; Sasaki, A; Sung, JH; Tokoro, S; Uojima, H	1
Chen, CW; Chen, YX; Cheng, J; Ding, HG; Han, T; Mao, Q; Mao, YM; Niu, JQ; Tang, JT; Wang, MR; Wang, YF; Wang, ZH; Wei, Z; Xie, Q; Yang, YP; Ye, WJ; Zeng, M	1
Abe, K; Fujita, M; Hayashi, M; Ohira, H; Okai, K; Takahashi, A	1
Abe, M; Hiasa, Y; Hirooka, M; Imai, Y; Koizumi, Y; Watanabe, T; Yoshida, O; Yukimoto, A	1
Atarashi, Y; Ito, H; Kawai, K; Minemura, M; Shimizu, Y; Sugiyama, T; Tajiri, K; Takahara, T; Tokimitsu, Y; Yasumura, S	1
Ding, HG; Han, T; Li, Y; Liebe, R; Ma, H; Wang, S; Weng, H; Xie, W; Zhang, X	1
Amin, A; Chiodo, JA; Sanyal, A; Sigal, SH	1
Hidaka, I; Ishikawa, T; Iwamoto, T; Maeda, M; Saeki, I; Sakaida, I; Tajima, K; Takami, T	1
Kodama, K; Kogiso, T; Sagawa, T; Taniai, M; Tokushige, K	1
Kida, Y	1
Akimoto, T; Kobayashi, T; Maeshima, A; Masuda, T; Matsuoka, R; Murakami, T; Muto, S; Nagata, D; Nagayama, I; Nakagawa, S; Ohara, K; Saito, O	1
Ando, H; Fukada, H; Kanazawa, R; Kokubu, S; Miyazaki, A; Nakadera, E; Okubo, H; Sagawa, E; Sorin, Y	1
Hidaka, H; Kako, M; Koizumi, W; Kubota, K; Nakazawa, T; Shibuya, A; Sung, JH; Tanaka, Y; Uojima, H; Wada, N	1
Ishihara, T; Isoai, A; Iwasa, M; Kato, M; Kobayashi, R; Soneda, N; Takei, Y; Torii, N	1
Aggarwal, S; Garg, R; Kaur, K; Singh, N	1
Kobayashi, T; Komatsu, M; Komorizono, Y; Okada, M; Okita, K; Sakai, T; Sakaida, I; Yamashita, S	1
Mager, DE; Mallikaarjun, S; Shoaf, SE; Van Wart, SA	1
Kwo, PY	1
Sakaida, I	1
Ahluwalia, V; Bajaj, JS; Feldman, G; Gavis, E; Gilles, H; Heuman, DM; Thacker, LR; Unser, A; Wade, JB; White, MB	1
Ding, HG; Dong, PL; Fan, CL; Li, B; Li, L; Li, P; Wang, SZ; Zhang, X; Zhao, WM; Zheng, JF	1
Goto, A; Matsumoto, M; Nakamura, M; Sakaida, I; Terai, S	1
Hori, M; Izumi, T; Kobayashi, H; Nakajima, K; Oka, H; Okita, K; Sakaida, I; Sakurai, M; Shibasaki, Y; Tachikawa, S; Tsubouchi, H	1
Hamano, T; Isaka, Y; Iwatani, H; Kawabata, H; Rakugi, H; Sakaguchi, Y; Yamamoto, R	1
Angelico, M; Baiocchi, L; Lenci, I; Milana, M	1
Hayashi, T; Higuchi, M; Hosokawa, T; Itakura, J; Izumi, N; Komiyama, Y; Kurosaki, M; Kuwabara, K; Nakakuki, N; Nakanishi, H; Sasaki, S; Suzuki, S; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Yasui, Y; Yoshida, T	1
Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Narahara, Y; Okubo, T; Tsubota, A	1
Nakajima, K; Sakaida, I; Shibasaki, Y; Tachikawa, S; Terai, S; Tsubouchi, H	1
Hayata, Y; Ito, D; Karasawa, Y; Kawamura, S; Kojima, K; Ohki, T; Seki, M; Tagawa, K; Toda, N; Yamada, T	1
Bhalla, A; Rai, N; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R	1
Angeli, P; Cárdenas, A; Ginès, P; Gola, E; Graupera, I; Guevara, M; Piano, S; Pose, E; Solà, E	1
Izumi, N; Kurosaki, M	1
Izumi, N; Kurosaki, M; Nakanishi, H	1
Tesař, V	1
Chayama, K; Kaneko, A; Kato, M; Murawaki, Y; Okada, M; Okita, K; Ono, N; Sakaida, I; Sata, M; Yoshihara, H; Yoshihara, N	1
Hutchinson, DJ; Nemerovski, C	1
Villabona, C	1
Elhassan, EA; Schrier, RW	1
Er, F; Fuhr, U; Gassanov, N; Nia, AM; Semmo, M; Semmo, N	1
Afdhal, NH; Cárdenas, A; Czerwiec, F; Ginès, P; Guevara, M; Marotta, P; Oyuang, J	1
Chiodo, J; Gaglio, P; Marfo, K	1
Dahl, E; Gluud, LL; Kimer, N; Krag, A	1
Kobayashi, Y; Okada, M; Okita, K; Sakaida, I; Yanase, M; Yasutake, T	1
Saab, S; Sharma, N; Yu, C	1
Berl, T; Czerwiec, FS; Gheorghiade, M; Gross, P; Orlandi, C; Schrier, RW; Verbalis, JG	1
Hood, VL; Rimmer, JM; Weise, WJ	1
Dawwas, MF	1
Arici, M; Kirkpantur, A; Ozkan, C	1
Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P	1
Głuszek, J; Olszewski, W	1

Reviews

14 review(s) available for tolvaptan and Cirrhosis, Liver

Article	Year
Hyponatremia in Cirrhosis: An Update. The American journal of gastroenterology, 2020, Volume: 115, Issue:11 Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Albumins; Antidiuretic Hormone Receptor Antagonists; Ascites; Fluid Therapy; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Hypertension, Portal; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Renin-Angiotensin System; Saline Solution, Hypertonic; Splanchnic Circulation; Tolvaptan; Vasodilation; Vasopressins	2020
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. International journal of molecular sciences, 2021, May-25, Volume: 22, Issue:11 Topics: Humans; Liver Cirrhosis; Tolvaptan	2021
Tolvaptan for the treatment of liver cirrhosis oedema. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:5 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Edema; Humans; Liver Cirrhosis; Tolvaptan; Treatment Outcome	2014
Management of ascites in cirrhotic patients. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2017, Volume: 114, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Ascites; Benzazepines; Diuretics; Humans; Japan; Liver Cirrhosis; Practice Guidelines as Topic; Receptors, Vasopressin; Signal Transduction; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Tolvaptan; Vasopressins	2017
Tolvaptan (Samsca) for hyponatremia. The Medical letter on drugs and therapeutics, 2009, Nov-30, Volume: 51, Issue:1326 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiomyopathy, Dilated; Clinical Trials as Topic; Drug Approval; Drug Interactions; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Osmolar Concentration; Tolvaptan; United States; United States Food and Drug Administration	2009
Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Clinical therapeutics, 2010, Volume: 32, Issue:6 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Volume; Dose-Response Relationship, Drug; Drug Interactions; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Randomized Controlled Trials as Topic; Sodium; Tolvaptan	2010
[Vasopressin receptor antagonists: the vaptans]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57 Suppl 2 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins	2010
Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Current opinion in nephrology and hypertension, 2011, Volume: 20, Issue:2 Topics: Adaptation, Physiological; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Brain; Exercise; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Tolvaptan	2011
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). European journal of clinical pharmacology, 2011, Volume: 67, Issue:4 Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Biological; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan; Water-Electrolyte Balance	2011
Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan. Digestive diseases and sciences, 2012, Volume: 57, Issue:11 Topics: Benzazepines; End Stage Liver Disease; Humans; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Outcome Assessment, Health Care; Tolvaptan	2012
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:7 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzamides; Benzazepines; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Sodium; Spiro Compounds; Tolvaptan; Treatment Outcome	2012
Hyponatremia: clinical associations, prognosis, and treatment in cirrhosis. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2013, Volume: 11, Issue:1 Topics: Benzazepines; Comorbidity; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Prevalence; Prognosis; Sodium; Tolvaptan	2013
Therapeutic potential of vasopressin receptor antagonists. Drugs, 2007, Volume: 67, Issue:6 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan	2007
[Vasopressin antagonists in treatment of hyponatremia]. Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:8 Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Sodium Chloride; Tolvaptan; Water-Electrolyte Balance	2007

Trials

16 trial(s) available for tolvaptan and Cirrhosis, Liver

Article	Year
Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC gastroenterology, 2020, Nov-19, Volume: 20, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; China; Diuretics; Humans; Liver Cirrhosis; Tolvaptan	2020
Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World journal of gastroenterology, 2017, Dec-07, Volume: 23, Issue:45 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tolvaptan; Treatment Outcome	2017
Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. Journal of digestive diseases, 2018, Volume: 19, Issue:3 Topics: Abdomen; Adolescent; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Sodium; Tolvaptan; Urine; Young Adult	2018
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC gastroenterology, 2018, Sep-04, Volume: 18, Issue:1 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Double-Blind Method; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Sodium; Survival Rate; Tolvaptan	2018
Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis. Digestive diseases (Basel, Switzerland), 2020, Volume: 38, Issue:1 Topics: Aged; Aged, 80 and over; Ascites; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Glomerular Filtration Rate; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Tolvaptan	2020
Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. The Journal of international medical research, 2013, Volume: 41, Issue:3 Topics: Aged; Ascites; Benzazepines; Body Weight; Diuretics; Drug Administration Schedule; Edema; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Protective Agents; Sodium; Tolvaptan; Treatment Outcome	2013
Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cross-Over Studies; Double-Blind Method; Female; Heart Failure; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Tolvaptan; Young Adult	2013
Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis. Journal of hepatology, 2015, Volume: 62, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Brain Edema; Cognition; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyponatremia; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Quality of Life; Sodium; Tolvaptan; Treatment Outcome	2015
Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. Journal of gastroenterology, 2015, Volume: 50, Issue:10 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Hyponatremia; Japan; Liver Cirrhosis; Male; Risk Assessment; Serum Albumin; Survival Rate; Tolvaptan	2015
Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. Journal of gastroenterology, 2017, Volume: 52, Issue:2 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Blood Urea Nitrogen; Body Weight; Female; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Tolvaptan; Urine	2017
Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:3 Topics: Adult; Ascites; Benzazepines; Drug Therapy, Combination; Female; Humans; India; Liver Cirrhosis; Male; Middle Aged; Midodrine; Pilot Projects; Sodium; Tertiary Care Centers; Time Factors; Tolvaptan; Vasoconstrictor Agents	2017
Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. The American journal of medicine, 2017, Volume: 130, Issue:3 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Headache Disorders, Primary; Humans; Liver Cirrhosis; Male; Middle Aged; Receptors, Vasopressin; Sodium; Tolvaptan; Treatment Outcome	2017
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. Journal of gastroenterology, 2010, Volume: 45, Issue:9 Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Dose-Response Relationship, Drug; Edema; Female; Furosemide; Humans; Japan; Liver Cirrhosis; Lower Extremity; Male; Middle Aged; Tolvaptan; Treatment Outcome; Waist Circumference	2010
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of hepatology, 2012, Volume: 56, Issue:3 Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Chronic Disease; Female; Health Surveys; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recurrence; Sodium; Tolvaptan; Treatment Outcome	2012
The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. The Journal of international medical research, 2012, Volume: 40, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Diuretics; Double-Blind Method; Electrolytes; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Tolvaptan	2012
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. The New England journal of medicine, 2006, Nov-16, Volume: 355, Issue:20 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Area Under Curve; Benzazepines; Double-Blind Method; Female; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Male; Middle Aged; Sodium; Tolvaptan	2006

Other Studies

42 other study(ies) available for tolvaptan and Cirrhosis, Liver

Article	Year
Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:21 Topics: Adipokines; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Biomarkers; Glycopeptides; Glycoproteins; Humans; Liver Cirrhosis; Tolvaptan; Zinc	2021
Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites. Scientific reports, 2022, 05-17, Volume: 12, Issue:1 Topics: Ascites; Humans; Liver Cirrhosis; Retrospective Studies; Thoracic Duct; Tolvaptan	2022
First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan. BMJ open gastroenterology, 2023, Volume: 10, Issue:1 Topics: Ascites; End Stage Liver Disease; Humans; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Quality of Life; Retrospective Studies; Severity of Illness Index; Tolvaptan	2023
Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis. Journal of gastroenterology, 2023, Volume: 58, Issue:7 Topics: Acute Kidney Injury; Acute-Phase Proteins; Ascites; Biomarkers; C-Reactive Protein; Humans; Lipocalin-2; Lipocalins; Liver Cirrhosis; Proto-Oncogene Proteins; Tolvaptan; Water	2023
[Research progress of arginine vasopressin V2 receptor antagonist tolvaptan in the treatment of cirrhotic ascites]. Zhonghua nei ke za zhi, 2023, Jul-01, Volume: 62, Issue:7 Topics: Ascites; Humans; Liver Cirrhosis; Receptors, Vasopressin; Sodium; Tolvaptan	2023
Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. Journal of gastroenterology, 2020, Volume: 55, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Female; Follow-Up Studies; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Muscle, Skeletal; Organ Size; Prognosis; Retreatment; Retrospective Studies; Sarcopenia; Survival Rate; Time Factors; Tolvaptan; Tomography, X-Ray Computed; Young Adult	2020
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Diuretics; Drug Therapy, Combination; Edema; Female; Furosemide; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Prognosis; Retrospective Studies; ROC Curve; Spironolactone; Survival Rate; Time Factors; Tolvaptan	2020
Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study. BMC gastroenterology, 2020, Mar-05, Volume: 20, Issue:1 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Fluids; Electric Impedance; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Monitoring, Physiologic; Tolvaptan	2020
Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). Journal of gastroenterology, 2020, Volume: 55, Issue:8 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Blood Urea Nitrogen; Edema; Female; Humans; Japan; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Tolvaptan; Treatment Outcome	2020
Durable response without recurrence to Tolvaptan improves long-term survival. Journal of gastroenterology, 2020, Volume: 55, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Time Factors; Tolvaptan; Treatment Outcome; Young Adult	2020
Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. Journal of gastroenterology, 2021, Volume: 56, Issue:1 Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Drug Therapy, Combination; Female; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Prognosis; Propensity Score; Retrospective Studies; Survival Analysis; Tolvaptan; Treatment Outcome	2021
Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models. Pharmacology research & perspectives, 2020, Volume: 8, Issue:5 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Cytokines; Heart Failure; Hyponatremia; Injections, Intraperitoneal; Kidney Function Tests; Lipid Peroxidation; Liver Cirrhosis; Male; Models, Animal; Oxidative Stress; Protective Agents; Rats; Receptors, Vasopressin; Renal Insufficiency; Tolvaptan	2020
A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:12 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Cell Adhesion Molecules; Genome-Wide Association Study; Humans; Liver Cirrhosis; Tolvaptan	2021
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan. Digestive diseases (Basel, Switzerland), 2022, Volume: 40, Issue:4 Topics: Ascites; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Prognosis; Renin; Retrospective Studies; Tolvaptan	2022
Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PloS one, 2017, Volume: 12, Issue:3 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Diuretics; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Potassium; Sodium; Tolvaptan; Treatment Outcome; Weight Loss	2017
Response criteria of tolvaptan for the treatment of hepatic edema. Journal of gastroenterology, 2018, Volume: 53, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Dose-Response Relationship, Drug; Edema; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Reproducibility of Results; Retrospective Studies; ROC Curve; Severity of Illness Index; Tolvaptan; Treatment Outcome; Weight Loss; Young Adult	2018
The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Internal medicine (Tokyo, Japan), 2017, Nov-15, Volume: 56, Issue:22 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Hyponatremia; Japan; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Sodium; Tolvaptan; Treatment Outcome	2017
Utility of Tolvaptan in the Perioperative Management of Severe Hyponatremia During Liver Transplantation: A Case Report. Transplantation proceedings, 2017, Volume: 49, Issue:10 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Tolvaptan	2017
Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia. Internal medicine (Tokyo, Japan), 2018, Sep-01, Volume: 57, Issue:17 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Sodium; Tolvaptan; Treatment Outcome	2018
Validation trial for efficacy of ultrasonographic measurement method to predict ascitic volume using virtual ultrasonography. Journal of medical ultrasonics (2001), 2018, Volume: 45, Issue:4 Topics: Abdomen; Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Humans; Imaging, Three-Dimensional; Liver Cirrhosis; Male; Middle Aged; Pelvis; Retrospective Studies; Tolvaptan; Tomography, X-Ray Computed; Ultrasonography	2018
Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Digestive diseases (Basel, Switzerland), 2018, Volume: 36, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; ROC Curve; Survival Analysis; Tolvaptan; Treatment Outcome	2018
Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry. Canadian journal of gastroenterology & hepatology, 2018, Volume: 2018 Topics: Aged; Antidiuretic Agents; Female; Fluid Therapy; Hospitalization; Humans; Hyponatremia; Isotonic Solutions; Liver Cirrhosis; Male; Middle Aged; Recurrence; Registries; Sodium; Tolvaptan; Treatment Outcome	2018
Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:7 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Drug Interactions; Drug Resistance; Female; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Tolvaptan; Treatment Outcome	2019
Impact of continued administration of tolvaptan on cirrhotic patients with ascites. BMC pharmacology & toxicology, 2018, Dec-18, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Ammonia; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Serum Albumin; Tolvaptan; Treatment Outcome; Young Adult	2018
Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites. Digestive diseases (Basel, Switzerland), 2019, Volume: 37, Issue:3 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Furosemide; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Tolvaptan; Treatment Outcome	2019
Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease. Internal medicine (Tokyo, Japan), 2019, Jun-01, Volume: 58, Issue:11 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Combination; Edema; Fluid Shifts; Furosemide; Humans; Leg; Liver Cirrhosis; Male; Renal Insufficiency, Chronic; Tolvaptan	2019
Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites. Journal of pharmacological sciences, 2019, Volume: 139, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Edema; Female; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Serum Albumin; Tolvaptan; Treatment Outcome	2019
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan. Internal medicine (Tokyo, Japan), 2019, Nov-01, Volume: 58, Issue:21 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Ascitic Fluid; Diuretics; Female; Fluid Therapy; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Product Surveillance, Postmarketing; Serum Albumin; Spironolactone; Tolvaptan	2019
Efficacy and Safety of Oral Tolvaptan Therapy in Hospitalized Cirrhotic Patients with Hyponatremia. The Journal of the Association of Physicians of India, 2018, Volume: 66, Issue:12 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Liver Cirrhosis; Prospective Studies; Tolvaptan	2018
Management of hyponatremia in clinical hepatology practice. Current gastroenterology reports, 2014, Volume: 16, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drinking Behavior; Fluid Therapy; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Spiro Compounds; Tolvaptan	2014
Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World journal of gastroenterology, 2014, Aug-28, Volume: 20, Issue:32 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Biomarkers; Edema; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Sodium; Time Factors; Tolvaptan; Treatment Outcome; Urination; Urodynamics	2014
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites. Clinical journal of gastroenterology, 2015, Volume: 8, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Furosemide; Humans; Liver Cirrhosis; Male; Spironolactone; Tolvaptan	2015
Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron, 2015, Volume: 130, Issue:1 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Heart Failure; Humans; Kidney Function Tests; Liver Cirrhosis; Male; Middle Aged; Osmolar Concentration; Renal Insufficiency, Chronic; Retrospective Studies; ROC Curve; Tolvaptan; Urodynamics; Weight Loss	2015
Short-Term, Low-Dose Use of Tolvaptan as a Bridge Therapy to Expedite Liver Transplant for Severe Hyponatremic, Cirrhotic Patients With High Model for End-Stage Liver Disease Scores. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:6 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Decision Support Techniques; Drug Administration Schedule; Fatal Outcome; Humans; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Severity of Illness Index; Time Factors; Tolvaptan; Treatment Outcome; Waiting Lists	2017
Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. Journal of gastroenterology, 2016, Volume: 51, Issue:6 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Ascites; Benzazepines; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tolvaptan	2016
Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World journal of gastroenterology, 2016, Jun-07, Volume: 22, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Edema; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Portal Pressure; Predictive Value of Tests; Prospective Studies; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance	2016
Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis. Clinical drug investigation, 2016, Volume: 36, Issue:10 Topics: Aged; Ascites; Benzazepines; Carcinoma, Hepatocellular; Diuretics; Female; Humans; Hyponatremia; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Tolvaptan	2016
Tolvaptan for the Treatment of Refractory Ascites. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:20 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Humans; Liver Cirrhosis; Tolvaptan	2016
[Current options of treatment of hyponatremia]. Vnitrni lekarstvi, 2016,Winter, Volume: 62 Suppl 6 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Europe; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Receptors, Vasopressin; Sodium; Tolvaptan; Vasopressins	2016
Tolvaptan for hyponatremia. The New England journal of medicine, 2007, Mar-01, Volume: 356, Issue:9 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Patient Dropouts; Tolvaptan; Water-Electrolyte Balance	2007
Tolvaptan for hyponatremia. The New England journal of medicine, 2007, Mar-01, Volume: 356, Issue:9 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Liver Cirrhosis; Patient Selection; Prognosis; Tolvaptan	2007
Tolvaptan for hyponatremia. The New England journal of medicine, 2007, Mar-01, Volume: 356, Issue:9 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Volume; Diuretics; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Tolvaptan	2007